Key Takeaway From 2-Year Follow-Up Data of ZUMA-1 Trial in Large B-Cell Lymphoma

Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.

Sattva S. Neelapu, MD, a professor in lymphoma and myeloma at MD Anderson Cancer Center, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma.

After a median follow-up of 27 months, overall survival (OS) has not been reached. According to Neelapu, this is an almost 4 month increase compared to historical data for traditional therapies where OS is expected to be around 6 months.